Physician profile
Adrienne Phillips
NPI 1619056157
$99,515.87
in general payments reported to CMS, 2019-2025
18 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $7,924 · 2021: $12K · 2022: $6,565 · 2023: $20K · 2024: $106 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Travel and Lodging: $6,166 · Food and Beverage: $2,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $34,306.82 |
| Travel and Lodging | $6,165.82 |
| Food and Beverage | $2,229.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $29,168.46 | 2019-2021 | |
| Kite Pharma, INC. | $13,698.27 | 2019-2023 | Yescarta |
| Genentech USA, INC. | $12,008.94 | 2024-2025 | Lunsumio, Columvi, Polivy |
| Genmab U.S., INC. | $9,654.94 | 2025 | Epkinly |
| Beigene USA, INC. | $9,281.16 | 2020-2021 | |
| Incyte Corporation | $6,858.95 | 2019-2025 | Jakafi, Niktimvo |
| E.R. Squibb & Sons, L.L.C. | $6,455.92 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $5,715.00 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,112.63 | 2019 | |
| Daiichi Sankyo INC. | $2,467.50 | 2021 | |
| Rigel Pharmaceuticals, INC. | $462.03 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Janssen Biotech, INC. | $270.22 | 2019-2025 | Carvykti, Rybrevant |
| Pharmacyclics LLC, An Abbvie Company | $99.00 | 2019 | |
| Stemline Therapeutics INC. | $91.87 | 2019 | |
| Eusa Pharma (US) LLC | $66.59 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $60.07 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $27.10 | 2019 | |
| Invivyd INC | $17.22 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrienne Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.